|
|||||||
|
|
|
|||||
|
|
|||||||
 | ||
Vioxx appeal to go before New Jersey court The New Jersey Supreme Court reportedly has agreed to hear Merck & Co.s appeal of the class certification of a Vioxx lawsuit. NJ Supreme Court to Hear Appeal on Vioxx New Jerseys Supreme Court will hear an appeal by Merck & Co. of a lower court ruling that would let health plans that paid for prescriptions of its withdrawn painkiller Vioxx sue as a class to recover billions of dollars. Firm finds niche with medical foods Scottsdale pharmaceutical company tackles arthritis market. COX-2 inhibitors prescribed to reduce gastrointestinal toxicity prior to the market withdrawals Nonsteroidal antiinflammatory drugs (NSAIDs) have been the most popular treatment for arthritis – despite their association with gastrointestinal (GI) complications, including bleeding ulcers and death. Garden State Business Briefs New Jerseys Supreme Court will hear an appeal by Merck of a lower court ruling that would let health plans that paid for prescrip tions of its withdrawn painkiller Vioxx sue as a class to recover billions of dollars. What a tangled web the Nuggets have woven The lawsuit that Nenes involved in could shed light on things tearing the Nuggets apart Tangled web has been woven in Denver A few weeks after the Nuggets season ended, Denver Post columnist Thomas George wrote a scintillating investigative account of the schisms that had developed within the team - schisms that strengthened the power of unofficial adviser Bret Bearup in the eyes of owner Stan Kroenke and led to the departure of former general manager Kiki Vandeweghe. Merck poised to rise as Street remains wary: report Merck & Co. Inc. , knocked low by the recall of its arthritis drug Vioxx, is poised to rise because Wall Street has failed to appreciate cost cutting and new products likely to generate bigger-than-expected sales, a report said. Wait for a Bad Day at Merck Folks seem to have gotten a lot more comfortable with Merck (NYSE: MRK) despite its potential liabilities in the blizzard of oncoming Vioxx lawsuits. Having apparently bottomed out in the mid-$20s, these shares are back up above $38 and sit at a 52-week high. Lawsuit Funding Network Helps Those in Need Days Away from Losing His Home, Client Gets a Cash Advance on his Zyprexa Claim. (PRWEB Jul 27, 2006) | ||